|Bid||11.9400 x 200|
|Ask||12.0300 x 100|
|Day's Range||11.5501 - 12.2950|
|52 Week Range||3.0100 - 22.3900|
|Beta (3Y Monthly)||3.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 10, 2018 - Dec 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.30|
- Mean HBsAg reduction of -1.9 Log10 with a range of -1.3 Log10 to -3.8 Log10
PASADENA, Calif.-- -- Three monthly doses of 300 mg ARO-AAT led to reductions in serum alpha-1 antitrypsin to below the level of quantitation in 100% of subjects Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible Single and multiple doses of ARO-AAT appear to be well-tolerated at all doses tested Arrowhead Pharmaceuticals Inc. today ...
The company de-risked the development of its potential blockbuster hepatitis B drug for a cool $250 million. Investors thought the price was too low.
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:
Arrowhead Pharmaceuticals Inc. today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the stock purchase agreement between Arrowhead and Johnson & Johnson Innovation – JJDC, Inc., have closed, following termination of the waiting period under ...
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In this daily bar chart of ARWR, below, we can see some strong price performance from December with prices rallying from $4 to touch $22 - impressive. The daily On-Balance-Volume (OBV) line shows an interesting rise from November to September. In this weekly bar chart of ARWR, below, we can see a parabolic rally from just $2 back in 2017 to $22 - one heck of a return.
Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform. In addition to senior members of the Arrowhead team, the R&D Day includes, Ira J. Goldberg, M.D., Bronfman Professor of Medicine, Chief of the Division of Endocrinology, Diabetes, and Metabolism, New York University Langone School of Medicine. A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
— Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics
Arrowhead Pharmaceuticals Inc. will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease being held on November 9-13, 2018, in San Francisco.
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
On October 4, Johnson & Johnson (JNJ) announced an exclusive worldwide license agreement with Arrowhead Pharmaceuticals (ARWR) to develop and commercialize the latter’s Phase 1/2 drug candidate for the treatment of chronic Hepatitis B viral infection.
When the market opened in 2018, Arrowhead Pharmaceuticals stock was selling at $3.69. Cantor Fitzgerald has raised its target price for Arrowhead Pharmaceuticals to $24 from $18. In July, Chardan Capital raised its price target to $24.50 from $17.50.
Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones ...
Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide licence for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology. J&J's investment comes a month after Arrowhead released data from an early trial testing ARO-HBV, dubbed "revolutionary" by analysts who also said the company was positioned to develop a functional cure for Hepatitis B. It also follows the first U.S. approval for an RNAi drug - Alnylam Pharmaceuticals' (ALNY.O) Onpattro - in August that affirmed the gene-silencing class of drugs as a new frontier in the field of medicine.
Arrowhead Pharmaceuticals touted a deal with Johnson & Johnson with a price tag more than the double the company’s market value, but the actual figure may be far smaller.